Turbo Cancers and Treatment by Melatonin

Young people, in their 20s, 30s, and 40s, are developing aggressive and rapidly-growing "turbo cancers."

Dr. William Makis, the Chief of Oncology at The Wellness Company (twc.health) and cancer researcher who has diagnosed 20,000 cancer patients in his career, says, "I've never seen anything like this."

Dr. Makis' full statement: “There are only a handful out of the 100,000 doctors, Canadian doctors, that didn't take the vaccine, that are still practicing medicine. So, it's something like 99.9% vaccination rate. And they were the first ones to line up for their vaccines. Well, as I started looking at the sudden deaths of Canadian doctors, I realized, yes, most of them are dying from cardiac issues, heart injuries, cardiac arrests, dying while jogging or swimming, dying in their sleep. And Dr. Peter McCullough has talked about this extensively, about the myocarditis and the damage to the heart, the scarring to the heart. And then some were dying from blood clots, pulmonary embolism, strokes.

But then there was quite a large subset of doctors who were developing extremely aggressive cancers and cancers at an age that they shouldn't be getting. So, for example, there was a doctor who developed gastric cancer in his 30s, presented at stage four. He was dead in less than a year. Very rare brain cancers in young individuals in their 20s and 30s, medical students, and medical residents. And these cancers would always present at stage four. And they would always kill them in a matter of a few months. And it was always less than a year.

And at first, I didn't know what the term for this was or what the phenomenon was. I just started really paying attention to it, tracking it. I then realized that this is being called “turbo cancer” by people on social media. Turbo cancer is not a medical term, but it's a term that people came up with to really describe the extremely aggressive nature of these cancers in the COVID-vaccinated. And these cancers behave completely differently, unlike anything I've seen before in my career. And I've diagnosed over 20,000 cancer patients in my career with cutting-edge PET, CT, positron emission tomography, imaging, CT, MRI, pathological correlation.

I've never seen anything like this. I've never seen stage four breast cancers presenting in women in their 20s. I've never seen stage four colon cancers presenting in men and women in their 20s and 30s. Leukemias that will kill you in a matter of days or even hours after diagnosis. Lymphomas that, again, kill you in a matter of months.”

According to clinical investigations, melatonin has the potential to prevent and cure cancer. Melatonin is crucial for tumor development. Low levels of Melatonin accelerate tumor development. At normal dose levels ranging from 10 to 50 mg/day, it can treat a variety of cancers in vivo (breast, lung, colon, liver, gastric, glioblastoma, ovarian, cervical, prostate, skin).

There is strong proof that it reduces adverse effects while improving the therapeutic benefits of chemotherapy and radiation. Due to its chemical characteristics, Melatonin has a restricted ability to penetrate mucosal and dermal barriers, has a shorter half-life, and is rapidly eliminated from blood circulation;

the use of Melatonin is currently limited due to its unfavorable pharmacokinetic properties. Nanoparticles are being developed to deliver Melatonin and potentially increase its use in cancer treatment.

Prostate cancer risk has been associated with exogenous factors that interfere with normal pineal secretory activity, including aging, poor sleep, and artificial light at night. Melatonin secretion becomes circadian between the age of one to three years and gradually diminishes by 10-15% per decade. Diminished lifetime secretion of melatonin has been suggested to be a catalyst for not only aging (dubbed “Age Clock”), but also age-related conditions like cancer.

Disruption of the circadian rhythm can increase the risk of cancer relationship between light exposure at night and the risk of prostate cancer. Several reports have correlated non-standard shift work and shift work sleep disorder with poor health consequences notably on men’s urologic health such as infertility, lower urinary tract symptoms, and prostate cancer. Significant increase in the risk of prostate cancer in rotating shift workers who alternate between a day and/or afternoon shift and a night shift

Melatonin action on prostate cancer cells: Melatonin prevents carcinogenesis by reducing genomic instability; Melatonin inhibits glucose metabolism of cancer cells; Melatonin inhibits DNA replication in cancer cells and cell proliferation;

Melatonin downregulates NF-kB activities leading to promote apoptosis and inhibit cell proliferation; Melatonin inhibits angiogenic processes; Melatonin attenuates androgen receptor activity; Melatonin inhibits metastasis by inhibiting enzymes that help cancer cells metastasize (Matrix metalloproteinases); Melatonin inhibits initiation and progression of cancers by modulating mitochondrial activity and function (melatonin improves mitochondrial function by inhibitory effect on Akt/mTOR path); Melatonin has anti-inflammatory effects on inflammatory cytokines like IL-17 that promote cancer; Melatonin has anti-cancer effects by resynchronizing the circadian rhythm; In previous clinical trials that investigated the anti-tumor effects of melatonin, the maintenance dose was mostly 20 mg per day and the duration varied from several weeks to some years.

“Considering that there were no major side effects related to melatonin except for minor psychological or neurocognitive problems, we recommend a higher dosage for a definite anti-tumor activity.”

extracted from makismd.substack.com on October 8, 2023